Table 2.

Event rates and hazard ratios of clinical outcomes associated with use of SGLT2is versus DPP4is (intention-to-treat analyses).

	SGLT2is (n = 21,329)		DPP4is (n = 21,329)		SDHR of SGLT2is versus DPP4is (95% CI)
	Number of events	Event rate (events/100 pys)	Number of events	Event rate (events/100 pys)
Primary outcomes
HHF	349	1.06	671	2.05	0.52 (0.45, 0.59)
3P-MACE†	409	1.24	656	1.98	0.62 (0.55, 0.70)
Secondary outcomes
4P-MACE‡	686	2.09	1,168	3.58	0.58 (0.53, 0.64)
Myocardial infarction	122	0.37	193	0.58	0.63 (0.50, 0.79)
Stroke	263	0.80	437	1.33	0.60 (0.51, 0.70)
All-cause death§	248	0.75	433	1.30	0.57 (0.49, 0.67)
Chronic kidney disease	979	3.19	2,003	7.00	0.46 (0.43, 0.50)
Amputation	35	0.11	55	0.17	0.64 (0.42, 0.98)
Hospitalized hypoglycemia	189	0.57	352	1.07	0.54 (0.45, 0.64)

SGLT2is, sodium glucose cotransporter-2 inhibitors; DPP4is, dipeptidyl peptidase-4 inhibitors; pys, person-years; SDHR, subdistribution hazard ratio; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular event.

^†3P-MACE included non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death.

^‡4P-MACE included non-fatal HHF, non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death.

^§Hazard ratio of all-cause death was estimated using the Cox proportional hazard model analysis instead of subdistribution hazard model analysis.